je.st
news
Tag: san antonio
San Antonio' top real estate agents continued to shine in 2014
2014-12-30 13:29:16| Real Estate - Topix.net
San Antonio's housing market yielded some of the strongest numbers this year, and the area's real estate agents saw a bump in their gross closing sales with it.
Uber, Lyft get mixed messages from San Antonio in 2014
2014-12-27 09:21:20| IT Services - Topix.net
Lyft and Uber drivers and supporters listen to a presentation in front of the San Antonio City Council. Ride-share companies say the new rules the city put in place are some of the most stringent in the country.
Uber, Lyft get mixed messages from San Antonio in 2014
2014-12-26 23:34:37| Telecom - Topix.net
Lyft and Uber drivers and supporters listen to a presentation in front of the San Antonio City Council. Ride-share companies say the new rules the city put in place are some of the most stringent in the country.
At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
2014-12-13 11:24:24| Biotech - Topix.net
Myriad Genetics, Inc. has announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
Tags: san
studies
antonio
cancer
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
2014-12-10 14:30:00| Merck.com - Corporate News
Dateline City: SAN ANTONIO 18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086) SAN ANTONIO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the companys anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer one of the most aggressive forms of breast cancer. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Claire Mulhearn, (908) 236-1118orInvestor:Joseph Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
san
presented
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »